Breaking News Instant updates and real-time market news.

NVS

Novartis

$84.45

-0.95 (-1.11%)

, BAYRY

Bayer

$0.00

(0.00%)

20:42
12/19/18
12/19
20:42
12/19/18
20:42

28 drugmakers set to raise prices starting in January, Reuters reports

Twenty eight drugmakers, including Novartis (NVS), Bayer (BAYRY), Allergan Plc (AGN), GlaxoSmithKline Plc (GSK), Amgen (AMGN), AstraZeneca Plc (AZN) and Biogen Inc (BIIB) will increase their prices beginning in January, Reuters reports, citing documents. The report states that the pharmaceutical companies filed notices with California agencies in November, which require the industry to provide 60-day notice before price hikes under a state law passed last year. Reference Link

NVS

Novartis

$84.45

-0.95 (-1.11%)

BAYRY

Bayer

$0.00

(0.00%)

AGN

Allergan

$136.58

-10.19 (-6.94%)

GSK

GlaxoSmithKline

$37.40

0.31 (0.84%)

AMGN

Amgen

$185.55

-1.61 (-0.86%)

AZN

AstraZeneca

$37.97

-0.26 (-0.68%)

BIIB

Biogen

$293.04

-1.46 (-0.50%)

  • 05

    Jan

  • 16

    Jan

NVS Novartis
$84.45

-0.95 (-1.11%)

12/07/18
FBCO
12/07/18
INITIATION
Target $6.5
FBCO
Outperform
Progenics initiated with an Outperform at Credit Suisse
Credit Suisse analyst Martin Auster initiated Progenics with an Outperform rating and $6.50 price target. In a research note to investors, Auster says he believes Progenics' royalties and future milestones from Relistor and revenue from Azedra support a core business with an NPV of about $5 per share, and says that as the commercial uptake of Azedra begins to unfold, investor focus is expected to turn to upside opportunities in prostate cancer PSMA-targeting diagnostic and therapeutic approaches. He adds that Novartis' (NVS) recent $2.1B acquisition of Endocyte (ECYT) supports pharma interest and attractive valuations in the space.
12/11/18
JEFF
12/11/18
INITIATION
Target $105
JEFF
Buy
Novartis assumed with a Buy at Jefferies
Jefferies analyst Peter Welford assumed coverage of GNovartis with a Buy rating and $105 price target. The analyst is positive on the European large-cap Pharma space "as it enters a period of sustained earnings momentum."
12/18/18
COWN
12/18/18
NO CHANGE
COWN
Outperform
Cowen sees Sandoz deal as reinforcing Tilray's competitive positioning
Tilray's (TLRY) expanded global partnership with Novartis (NVS) division Sandoz can not only help expand its reach with pharmacists, physicians and distributors, it can also help Tilray capture early share in new medical cannabis markets as they come online, Cowen analyst Vivien Azer tells investors in a research note. Further, the analyst believes the partnership also helps legitimize cannabis in international markets, which could help influence countries considering medical cannabis legalization. Azer estimates international will represent 15% of Tilray's revenue in fiscal 2020 and 22% in fiscal 2021. Not only does the deal allow Tilray to expand geographic reach, but also to grow at scale, says Azer. And most notably, the Sandoz deal reinforces Tilray's competitive positioning, adds the analyst, who keeps an Outperform rating on the shares with a $150 price target. The stock in morning trading is up 9%, or $5.98, to $71.87.
12/07/18
LEHM
12/07/18
DOWNGRADE
LEHM
Underweight
Novartis downgraded to Underweight from Equal Weight at Barclays
BAYRY Bayer
$0.00

(0.00%)

12/17/18
MSCO
12/17/18
NO CHANGE
Target $153
MSCO
Equal Weight
J&J stock reaction, comparisons to Bayer 'flawed,' says Morgan Stanley
Morgan Stanley analyst David Lewis said he is not convinced that Friday's article from Reuters uncovered new evidence that was not presented to Johnson & Johnson (JNJ) juries or part of the ongoing legal discovery process, but that it has raised a level of awareness around the issue and may inflate the company's potential legal exposure. The stock reaction is not supported by science as linking ovarian cancer broadly to talc will be challenging, contends Lewis, who believes the selloff in J&J shares appears too severe. Additionally, investor concerns that talc issues could lead to a Bayer-like (BAYRY) reaction have a flaw in the analysis of financial exposure, as glyphosate and its derivatives represent about 30% of Bayer's corporate EBITDA, while baby powder is less than 0.3% of J&J's sales and an "immaterial" percentage of EBITDA, said Lewis. He maintains an Equal Weight rating on Johnson & Johnson with a price target of $153.
09/20/18
SBSH
09/20/18
UPGRADE
SBSH
Buy
Bayer upgraded to Buy from Neutral at Citi
Citi analyst Peter Verdult upgraded Bayer to Buy saying the current risk/reward is "difficult to ignore" with investor sentiment at "rock bottom." The analyst believes the negative earnings revisions have likely bottomed out.
12/04/18
FBCO
12/04/18
NO CHANGE
Target $113
FBCO
Outperform
FMC Corporation price target raised to $113 from $105 at Credit Suisse
Credit Suisse analyst Christopher Parkinson raised his price target for FMC Corporation (FMC) to $113 from $105 as he believes the company is making impressive strides to solidify itself within the "Big 5" alongside Bayer (BAYRY), Syngenta, BASF (BASFY) and DowDuPont (DWDP) post a large round of consolidation. The analyst reiterates an Outperform rating on the shares.
11/27/18
MSCO
11/27/18
NO CHANGE
Target $208
MSCO
Overweight
Loxo approval expected, pricing higher than expected, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Loxo Oncology's (LOXO) Vitrakvi was approved with a broad label, as expected. Reuters reported, citing Bayer's (BAYRY) VP of pricing and contracting, that Vitrakvi will be priced at $32,800/month. Assuming a real-world ORR of about 70%, he estimates net annualized pricing of about $300,000/patient, which Harrison said is 50% above his expectation and he would expect a similar amount above consensus. The analyst, who thinks the upside pricing makes consensus estimates "very achievable" for 2019, keeps an Overweight rating on Loxo shares, which he expects will be up "modestly" on the news.
AGN Allergan
$136.58

-10.19 (-6.94%)

12/19/18
JPMS
12/19/18
NO CHANGE
JPMS
Overweight
Allergan selloff today an overreaction, says JPMorgan
12/19/18
JPMS
12/19/18
NO CHANGE
JPMS
Overweight
Allergan selloff on breast implant suspension an overreaction, says JPMorgan
JPMorgan analyst Chris Schott views the 6% selloff in shares of Allergan on the company suspending sales of its textured breast implants in Europe following a recall request by French regulators as an overreaction. The product represents less than 1% of Allergan's $15.7B of revenue in 2018, and French regulators have not identified any immediate risk to women with textured breast implants, Schott tells investors in an intraday research note. Allergan at current share levels is trading at a significant discount to the group, adds the analyst. He keeps an Overweight rating on name. The stock in late morning trading is down $8.66 to $138.10.
12/19/18
LEER
12/19/18
NO CHANGE
LEER
Outperform
Allergan selloff today a buying opportunity, says Leerink
Leerink analyst Marc Goodman views today's 7% selloff in shares of Allergan based on the breast implant news as a buying opportunity. While the suspension of sales is an incremental negative and likely to bring down consensus numbers, 2019 should bring increasingly visibility for Botox durability and the company's the pipeline, Goodman tells investors in a research note. He keeps an Outperform rating on Allergan, which is down $11.01 to $135.82 in afternoon trading.
12/19/18
RAJA
12/19/18
NO CHANGE
Target $198
RAJA
Outperform
Selloff in Allergan shares 'overdone,' says Raymond James
Raymond James analyst Elliot Wilbur notes that the French regulatory authority ANSM has issued a communique indicating that Allergan's CE Mark for the company's line of textured breast implants sold in various European countries will not be renewed based on input from GMED, the official French medical device certification body. Allergan can no longer sell textured breast implants in France and other affected European markets, and the company has ceased sales and commenced a recall of all existing supply, he adds. The analyst acknowledges that this is a "surprise but certainly not an unknown." Further, Wilbur believes reaction is "overdone" and shares should be "aggressively accumulated" on the move. He reiterates an Outperform rating and $198 price target on the stock.
GSK GlaxoSmithKline
$37.40

0.31 (0.84%)

12/14/18
LEER
12/14/18
NO CHANGE
LEER
Outperform
Tesaro proxy documents point to interest in PARP economics, says Leerink
Leerink analyst Andrew Berens noted that GlaxoSmithKline (GSK) and Tesaro (TSRO) disclosed background details for their deal agreement in a filing this morning. The documents show several parties were interested in a strategic transaction with Tesaro at various points over the last year, though the strategic interest appears to have been driven by Glaxo and one additional company, identified as "Party A", Berens said. It is not clear why the six other contacted parties were not interested in pursuing a strategic transaction, but he thinks Party A's co-promote proposal and the initial interest of other potential acquirers indicates strategic interest in the economics surrounding a PARP. Berens, who continues to see Clovis (CLVS) being well-positioned as the remaining stand-alone PARP-focused company, keeps an Outperform rating on Clovis and Market Perform rating on Tesaro.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
12/13/18
RHCO
12/13/18
INITIATION
RHCO
Hold
GlaxoSmithKline initiated with a Hold at SunTrust
SunTrust analyst John Boris initiated GlaxoSmithKline with a Hold rating and $38 price target, expecting the company's respiratory franchise to stagnate with Advair generic competition expected in the near-term.
12/14/18
12/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at Wedbush and a Hold at Deutsche Bank. 2. New York Times (NYT) initiated with an Outperform at Evercore ISI. 3. Ford (F) and General Motors (GM) were initiated with a Buy at Deutsche Bank, while Autoliv (ALV) was initiated with a Sell. 4. AstraZeneca (AZN) initiated with a Buy at SunTrust while GlaxoSmithKline (GSK) was initiated with a Hold. 5. DaVita (DVA) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AMGN Amgen
$185.55

-1.61 (-0.86%)

10/29/18
PIPR
10/29/18
NO CHANGE
PIPR
Neutral
Piper sees Amgen's Aimovig pressuring Allergan's Botox in near term
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Amgen (AMGN) and Neutral rating on Allergan (AGN) after his firm's Overweight based on feedback from a migraine survey fielded by his firm's partner Spherix Global Insights. The analyst is "struck by the progress" Amgen has made just months into Aimovig's launch, specifically on sales coverage, message delivery and overall credibility with physicians. It appears that Allergan's Botox "could be in for some pressure in the near term at the direct hands" of Amgen's Aimovig, Raymond tells investors in a research note titled "Aiming for Aimovig; New Migraine Survey Indicates Aimovig the Star of the Show." Doctors are projecting peak Aimovig share of 49% and 29% for chronic and episodic patients respectively, which infers peak U.S. revenue for the drug at $3.3B, the analyst says. Further, he notes that of the 98 high volume migraine specialists surveyed, 43% versus 29% agreed with the statement: "I am more likely to prescribe Aimovig over Botox due to access to patient assistance program."
10/31/18
RBCM
10/31/18
NO CHANGE
Target $182
RBCM
Sector Perform
Amgen price target lowered to $182 from $193 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Amgen to $182 and kept his Sector Perform rating after its Q3 results. The analyst says the quarter was "in line" with "safe" expectations, even as the company's core business competition is "slow" to impact sales. MacKay further cites an "astonishing" launch of Aimovig with 100K new patients, but also notes the sales decline against sequential volume growth for Amgen's Repatha.
11/19/18
CANT
11/19/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro could be worth $89-$97 per share in buyout, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young believes Tesaro (TSRO) could be valued at $89-$97 per share in a takeout scenario. The stock closed Friday up 31%, or $8.37, to $34.96 after Bloomberg reported that the company was exploring a sale after receiving some interest. The press article could be a way of garnering interest for the company beyond potentially initial interest, Young tells investors in a research note. In the past, she thinks Tesaro has been a potential takeout interest from biopharmaceutical companies. Companies like Amgen (AMGN), Gilead (GILD), and Celgene (CELG) have cancer platforms that could add a PARP inhibitor and benefit from Tesaro's various immuno-oncology pipeline assets, Young writes. She reiterates an Overweight rating on Tesaro with a $68 price target.
12/18/18
HCWC
12/18/18
DOWNGRADE
HCWC
Neutral
Advaxis downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth downgraded Advaxis (ADXS) to Neutral without a price target. Amgen's (AMGN) termination of a development and collaboration agreement puts ADXS-NEO in limbo, Ramakanth tells investors in a research note. The analyst believes Amgen's withdrawal has "considerably increased" the development risk on ADXS-NEO and potentially ADXS-HOT as well. He steps to the sidelines "until the viability of the programs can be assured."
AZN AstraZeneca
$37.97

-0.26 (-0.68%)

12/13/18
RHCO
12/13/18
INITIATION
RHCO
SunTrust sees oncology fueling growth for AstraZeneca through 2022
SunTrust analyst John Boris initiated AstraZeneca with a Buy rating and $48 price target, saying oncology should fuel growth through 2022 -- supported by label expansion of its in-line products and new launches -- as well as growth accelerated by 2019 pipeline catalysts.
12/13/18
RHCO
12/13/18
INITIATION
Target $48
RHCO
Buy
AstraZeneca initiated with a Buy at SunTrust
SunTrust analyst John Boris started AstraZeneca with a Buy rating and $48 price target.
12/12/18
PIPR
12/12/18
NO CHANGE
PIPR
Piper Jaffray reiterates Overweight on Aveo after AstraZeneca partnership
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $5 price target on Aveo Oncology (AVEO), after the company announced a partnership with AstraZeneca (AZN) to conduct a Phase I/II study of durvalumab + tivozanib in in first-line liver cancer. The analyst also noted that, following positive Phase III TIVO-3 data in 3rd+ line RCC for tivozanib, Aveo intends to file an NDA in the first half of 2019 with mature OS data likely in Q3 of 2019. Tenthoff expects FDA approval and launch in 2020 forecasting U.S. sales of $32M in 2020 growing to $218M in 2025.
BIIB Biogen
$293.04

-1.46 (-0.50%)

12/18/18
OPCO
12/18/18
NO CHANGE
Target $372
OPCO
Outperform
Biogen price target lowered to $372 from $380 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Biogen to $372 from $380 after co-hosting a call with a neurology expert to focus on several neuromuscular disorders and explore recent thoughts about spinal muscular atrophy. While Spinraza has a positive impact on maintaining independence, gene therapy and oral treatment are potential threats, and some reimbursement challenges facing Spinraza could be amplified with new modalities such as gene therapy, he contends. The analyst reiterates an Outperform rating on the shares.
12/18/18
PIPR
12/18/18
NO CHANGE
Target $400
PIPR
Overweight
Piper says Biogen weakness on Tecfidera patent concerns a buying opportunity
Piper Jaffray analyst Christopher Raymond attributes today's weakness in Biogen (BIIB) shares to a competitor's research note that raised concerns about Mylan's (MYL) IPR challenge of Tecfidera's '514 dosing patent. While acknowledging that a worst case scenario does remove about $50 per share from his sum-of-the-parts valuation for Biogen, Raymond said his read of the current case, along with the fact that the '514 patent previously survived Forward Pharma's 2014 interference claim and Hayman Capital's IPR in 2015, lead him to view such scenario as "very low probability." The analyst, who views the weakness as a buying opportunity, keeps an Overweight rating and $400 price target on Biogen shares, which are down 7% to $291.31 in afternoon trading.
12/18/18
BERN
12/18/18
NO CHANGE
Target $288
BERN
Market Perform
Biogen drops after Bernstein sees potential downside of $100 on Q1 risks
Bernstein analyst Aaron Gal earlier today lowered his price target for Biogen (BIIB) to $288 from $341 while keeping a Market Perform rating on the shares. The Biogen "debate" revolves primarily around three elements: the durability of the existing franchises, the value of the company's Alzheimer's opportunity, and the potential of the pipeline to generate new drugs, Gal wrote in a research note. He believes the stock's current risk/reward balance "captures these dynamics." In Q1 of 2019, however, Biogen is facing "two significant risks," says the analyst. These are the inter partes review institution decision on its biggest drug, Tecfidera, and futility analyses of amyloid beta drugs - Roche's (RHHBY) crenezumab and potentially Biogen's own aducanumab, according to Gal. The analyst views Biogen's near-term risk/reward as "sharply negative." If a review of Tecfidera is instituted and one of the amyloid beta trials is stopped for futility, the stock "can easily" trade $100 per share lower, Gal believes. Even if one of these events goes against the company, the analyst thinks the Biogen can drop $30-$80 per share. On the other hand, passing both risks will likely only have "moderate upside" of around $30 per share as "both are assumed to be positive in sell-side consensus," Gal writes. He keeps a Market Perform rating on Biogen, which is down 7%, or $21.45, to $291.66 in afternoon trading.
12/19/18
MZHO
12/19/18
NO CHANGE
Target $313
MZHO
Buy
Biogen traded down yesterday on 'not new' concerns, says Mizuho
Mizuho analyst Salim Syed attributes the selloff yesterday in shares of Biogen to "not new" and "simply re-surfaced" concerns of the Tecfidera inter partes review and Crenzumab's upcoming futility test. While these are both risks to Biogen, it is important to keep these two risks in perspective, Syed tells investors in a research note. Based on "actual, empirical data," there is only a 19% chance that Biogen's '514 patent is ruled unpatentable, says the analyst. And regarding the upcoming Roche/AC Immune Crenezumab futility analysis, Syed is "skeptical" to draw much read-through to Biogen's Aducanumab. The analyst keeps a Buy rating on Biogen with a $313 price target.

TODAY'S FREE FLY STORIES

SYF

Synchrony

$33.97

0.48 (1.43%)

, SLB

Schlumberger

$31.90

-0.06 (-0.19%)

20:25
10/17/19
10/17
20:25
10/17/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

SYF

Synchrony

$33.97

0.48 (1.43%)

SLB

Schlumberger

$31.90

-0.06 (-0.19%)

AXP

American Express

$119.17

1.76 (1.50%)

KO

Coca-Cola

$53.80

0.31 (0.58%)

STT

State Street

$59.71

0.57 (0.96%)

CFG

Citizens Financial

$35.01

-0.12 (-0.34%)

KSU

Kansas City Southern

$135.33

1.04 (0.77%)

GNTX

Gentex

$27.57

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 27

    Oct

  • 04

    Nov

  • 13

    Nov

  • 06

    Dec

PLSE

Pulse Biosciences

$14.52

0.525 (3.75%)

20:10
10/17/19
10/17
20:10
10/17/19
20:10
Hot Stocks
Pulse Biosciences to present data from studies of nano-pulse stimulation at ASDS »

Pulse Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TW

Tradeweb Markets

$43.20

0.87 (2.06%)

19:50
10/17/19
10/17
19:50
10/17/19
19:50
Syndicate
Tradeweb Markets 17.29M share Secondary priced at $42.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

SWDAF

Software AG

$0.00

(0.00%)

19:33
10/17/19
10/17
19:33
10/17/19
19:33
Upgrade
Software AG rating change  »

Software AG upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$14.43

-0.22 (-1.50%)

18:57
10/17/19
10/17
18:57
10/17/19
18:57
Hot Stocks
Petrobras reports Q3 production 2.878M boepd, up 9.3% »

Petrobras said it posted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

MRTN

Marten Transport

$21.52

0.31 (1.46%)

, ISRG

Intuitive Surgical

$529.22

-1.25 (-0.24%)

18:49
10/17/19
10/17
18:49
10/17/19
18:49
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MRTN

Marten Transport

$21.52

0.31 (1.46%)

ISRG

Intuitive Surgical

$529.22

-1.25 (-0.24%)

ETFC

E-Trade

$39.04

0.02 (0.05%)

WAL

Western Alliance

$46.24

0.53 (1.16%)

TEAM

Atlassian

$122.43

-1.91 (-1.54%)

PRTK

Paratek Pharmaceuticals

$3.46

0.05 (1.47%)

GIL

Gildan Activewear

$35.38

0.095 (0.27%)

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

EXPO

Exponent

$70.82

1.34 (1.93%)

WDFC

WD-40

$182.75

2.41 (1.34%)

VICR

Vicor Corporation

$32.78

1.16 (3.67%)

OZK

Bank OZK

$28.32

0.03 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 27

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 06

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 19

    Nov

  • 22

    Nov

ARWR

Arrowhead

$36.61

2.11 (6.12%)

, AMGN

Amgen

$203.60

0.32 (0.16%)

18:43
10/17/19
10/17
18:43
10/17/19
18:43
Hot Stocks
Arrowhead CEO: We can silence a single gene »

In an interview on…

ARWR

Arrowhead

$36.61

2.11 (6.12%)

AMGN

Amgen

$203.60

0.32 (0.16%)

JNJ

Johnson & Johnson

$136.20

1 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

  • 07

    Dec

SXT

Sensient

$66.57

0.4 (0.60%)

18:32
10/17/19
10/17
18:32
10/17/19
18:32
Hot Stocks
Sensient raises quarterly dividend 8.3% to 39c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

T

AT&T

$37.82

0.03 (0.08%)

18:31
10/17/19
10/17
18:31
10/17/19
18:31
Periodicals
HBO Max to stream Studio Ghibli films, Reuters says »

AT&T's upcoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 18

    Nov

  • 19

    Nov

OMAB

OMA

$52.10

0.47 (0.91%)

18:19
10/17/19
10/17
18:19
10/17/19
18:19
Earnings
OMA reports Q3 net income MXN858M vs. MXN725M last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

MAR

Marriott

$120.57

-0.55 (-0.45%)

18:13
10/17/19
10/17
18:13
10/17/19
18:13
Periodicals
Marriott near deal for Elegant Hotels valued up to GBP1 / shr, Bloomberg says »

The report states that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

SPY

SPDR S&P 500 ETF Trust

$299.19

0.78 (0.26%)

, SPX

S&P 500

$0.00

(0.00%)

18:08
10/17/19
10/17
18:08
10/17/19
18:08
General news
NY Fed's Williams Condition in money markets highly volatile over past month »

Williams says:…

SPY

SPDR S&P 500 ETF Trust

$299.19

0.78 (0.26%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$36.20

-0.45 (-1.23%)

17:47
10/17/19
10/17
17:47
10/17/19
17:47
Periodicals
GM strike to continue until deal with UAW is ratified, WSJ says »

United Auto Workers union…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

T

AT&T

$37.82

0.03 (0.08%)

17:37
10/17/19
10/17
17:37
10/17/19
17:37
Periodicals
AT&T, Elliott Management in talks to resolve activist campaign, WSJ reports »

AT&T is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 18

    Nov

  • 19

    Nov

WAL

Western Alliance

$46.24

0.53 (1.16%)

17:27
10/17/19
10/17
17:27
10/17/19
17:27
Earnings
Western Alliance reports Q3 EPS $1.24, consensus $1.19 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 30

    Oct

  • 31

    Oct

  • 06

    Nov

RNLSY

Renault

$0.00

(0.00%)

17:25
10/17/19
10/17
17:25
10/17/19
17:25
Downgrade
Renault rating change at Deutsche Bank »

Renault downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOVE

Lovesac

$19.10

0.63 (3.41%)

17:24
10/17/19
10/17
17:24
10/17/19
17:24
Hot Stocks
Park West Management reports 5.1% passive stake in Lovesac »

Park West Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

T

AT&T

$37.82

0.03 (0.08%)

17:24
10/17/19
10/17
17:24
10/17/19
17:24
Periodicals
Breaking Periodicals news story on AT&T »

AT&T in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 18

    Nov

  • 19

    Nov

ATVI

Activision Blizzard

$55.60

0.01 (0.02%)

17:16
10/17/19
10/17
17:16
10/17/19
17:16
Hot Stocks
Activision says Call of Duty to get 'battle pass' feature, 'not loot box system' »

Activision's Call of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 07

    Nov

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:11
10/17/19
10/17
17:11
10/17/19
17:11
Hot Stocks
Brandywine Realty sees FY19 year-end core occupancy at 94%-95% »

Also sees FY20 year-end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:10
10/17/19
10/17
17:10
10/17/19
17:10
Hot Stocks
Brandywine Realty reports Q3 same-store net operating income up 0.6% »

Reports Q3 occupancy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:09
10/17/19
10/17
17:09
10/17/19
17:09
Earnings
Brandywine Realty sees FY20 initial FFO $1.41-$1.51, consensus $1.46 »

Sees FY20 same-store net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

GIL

Gildan Activewear

$35.38

0.095 (0.27%)

17:08
10/17/19
10/17
17:08
10/17/19
17:08
Earnings
Gildan Activewear cuts FY19 adj. EPS view to $1.65-$1.70 from $1.95-$2.00 »

Consensus $1.97. Cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:07
10/17/19
10/17
17:07
10/17/19
17:07
Earnings
Brandywine Realty narrows FY19 FFO guidance to $1.41-$1.43 from $1.40-$1.44 

Consensus $1.42.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:07
10/17/19
10/17
17:07
10/17/19
17:07
Earnings
Brandywine Realty reports Q3 FFO 36c, consensus 36c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.